Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Nov 23, 2022 12:30pm

217 Views

Post# 35122350

RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

Thanks for the valuable posts on timing of results.

I have been wondering about the onset of the 16 week period myself.

We can only wait.

But we also wonder:

"It's quiet out there."

"Yeah. Too quiet."

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario